n-3 Polyunsaturated fatty acids in the treatment of patients with IgA nephropathy

Grande, Joseph P.; Donadío, James V.

doi:10.1007/978-3-0348-8825-7_10

Search citation statements

Order By: Relevance

Paper Sections

Select...

N¡3 Polyunsaturated Fatty Acids1

Fish Oils?1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2000

2002

Publication Types

Select...

Article2

Relationship

Self Cite1

Independent1

Authors

Journals

Cited by 2 publications

(2 citation statements)

References 66 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…88,89 The efficacy of fish oil has been tested in patients with IgA nephropathy in four randomized trials, with varying results; two showed that treatment stabilized renal function, 90,91 and two reported a decline in renal function. 92,93 A meta-analysis of these four randomized trials plus a small, nonrandomized study 94 showed that the probability of at least a minor beneficial effect on the preservation of renal function was 75 percent.…”

Section: N¡3 Polyunsaturated Fatty Acidsmentioning

confidence: 99%

IgA Nephropathy

Donadío¹,

2002

Self Cite

View full text Add to dashboard Cite

Section: N¡3 Polyunsaturated Fatty Acidsmentioning

confidence: 99%

IgA Nephropathy

Donadío¹,

2002

Self Cite

View full text Add to dashboard Cite

“…Inevitably there is the controversial topic of ®sh oil therapy for IgA nephropathy. The theoretical principle is certainly attractive (79). When ingesting ®sh oils, ie the 20:5 unsaturated fatty acids EPA (eicosapentaenoic acid) together with DHA (docosahexaenoic acid), the synthesis of harmful thromboxane A2 should be diminished and instead a weak TxA3 is formed.…”

Section: Fish Oils?mentioning

confidence: 99%

RATIONALES FOR TREATING IgA NEPHROPATHIES

Wardle¹

2000

Renal Failure

View full text Add to dashboard Cite

An outline is given of the pathophysiology of IgA nephropathy (IgA) in order to emphasize the role of eicosanoids, angiotensin II, and reactive oxygen species. ACE inhibitors and early corticosteroid usage are prime therapies. Tonsillectomy is to be considered, certainly for individual cases. It is logical that other components of a cocktail could be (i) thromboxane antagonists, (ii) leukotriene antagonists, or (iii) PAF antagonist. In theory there should be benefit from antioxidants. Fish oils have not come up to expectation. PDGF aptamers look promising for the prevention of mesangial cell proliferation. Heparins are not used in the way that they could be. Various other agents could help reduce decline.

show abstract

n-3 Polyunsaturated fatty acids in the treatment of patients with IgA nephropathy

Cited by 2 publications

References 66 publications

IgA Nephropathy

IgA Nephropathy

RATIONALES FOR TREATING IgA NEPHROPATHIES

Contact Info

Product

Resources

About